Form 4: Ginkgo Bioworks Director Myrtle S. Potter Reports Stock Option and RSU Awards

Director Myrtle S. Potter reports the acquisition of stock options and restricted stock units (RSUs) in Ginkgo Bioworks Holdings, Inc.

Summary

• Myrtle S. Potter, a director of Ginkgo Bioworks Holdings, Inc., filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the acquisition of stock options and restricted stock units (RSUs) on June 13, 2024.
• Potter acquired 1,111,111 stock options with an exercise price of $0.462, valued at $400,000, vesting in equal installments over three years.
• An additional 571,428 stock options with an exercise price of $0.462, valued at $200,000, were also acquired, vesting prior to the next Annual Meeting of Shareholders.
• Potter also acquired 432,900 RSUs, each representing a contingent right to receive one share of Class A Common Stock, vesting prior to the next Annual Meeting of Shareholders.
• All awards are subject to continued service as a Non-Employee Director.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of equity compensation is a standard practice and indicates alignment between the director and the company's success. There are no explicitly negative aspects in the filing.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.
• The vesting schedules incentivize long-term commitment from the director.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and RSUs, which are contingent on continued service as a Non-Employee Director.

Industry Context

This filing is a routine disclosure of equity compensation for a director, which is a common practice in publicly traded companies to align the interests of directors with those of shareholders. It's typical for biotech companies like Ginkgo Bioworks to use stock options and RSUs as part of their compensation packages.

Comparison to Industry Standards

• Equity compensation for board members is a standard practice across publicly traded companies, particularly in the biotech sector.
• Companies like Amyris and Zymergen (before its acquisition) also utilized stock options and RSUs to compensate and incentivize their directors.
• The vesting schedules and valuation methods (e.g., Black-Scholes) are consistent with industry norms for director compensation packages.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning the director's interests with the company's long-term performance.
• Employees may see this as a standard part of the company's compensation practices.

Next Steps

• The director will continue to serve as a Non-Employee Director to fulfill the vesting requirements of the stock options and RSUs.
• The company will likely disclose similar equity grants in future filings.

Key Dates